Overview Article

Approach to the patient with advanced differentiated thyroid cancer

1Schlumberger M. and 2Sherman SI

1Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence “Tumeurs Réfractaires de la Thyroïde”, Institut Gustave Roussy and University Paris-Sud XI, 94800 Villejuif, France.
2Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Correspondence:
Martin Schlumberger
Institut Gustave Roussy
94800 Villejuif, France
E-mail: schlumbg@igr.fr
Fax: +33142116363
Tel: +33142116095

Search strategies : all papers written in English found on PubMed between 2000-2010 using the key words “metastatic thyroid cancer, radioiodine, targeted therapies” were analyzed.
Abstract
Patients with advanced thyroid cancer may benefit from l-thyroxine treatment at doses that suppress serum TSH level, local treatment interventions and radioiodine therapy. In those patients who are refractory to radioiodine therapy and in whom progressive disease has been documented, the efficacy of cytotoxic chemotherapy is poor. Encouraging results have been obtained with the use of kinase inhibitors that should be offered as first line treatment, preferably in the context of a prospective trial.

Key words: refractory thyroid cancer; targeted therapy
INTRODUCTION AND BACKGROUND

Differentiated Thyroid Cancer (DTC) accounts for more than 90% of all thyroid cancers, and includes the papillary, follicular and poorly differentiated histologic types. In patients with clinical cancer, initial treatment includes a total thyroidectomy and a lymph node dissection in those with known or at a high risk of lymph node metastases. Radioiodine treatment is administered post-operatively in patients with a significant risk of recurrence or of disease related mortality\(^1\). Then, annual follow-up is performed on thyroxine treatment and is based on neck ultrasonography and on serum thyroglobulin determination. The use of recombinant human TSH stimulation may permit the early detection of persistent or recurrent disease\(^1\).

Recurrent disease occurs in 10-15%, mostly in patients with extensive disease (large thyroid tumors, extension beyond the thyroid capsule, lymph node metastases) and in those with an aggressive histologic type\(^1\,\text{-}\,4\). In 3/4 of cases, recurrent disease is located in the neck only, in lymph nodes or in the thyroid bed. In patients with persistent or recurrent disease, levothyroxine therapy is given at doses that suppress thyroid stimulating hormone (TSH), because increased serum TSH level may enhance tumor growth\(^5\,\text{,}\,6\). Treatment of neck recurrence includes surgery, radioiodine and in some patients external radiation therapy\(^7\). Complete remission is achieved in more than two thirds of patients with recurrent disease in lymph nodes, but recurrences in the thyroid bed are often associated with a poorer prognosis.

Distant metastases are observed in fewer than 10% of DTC patients, with half of them being detected at presentation. They are located in the lungs (50%), bones (25%), lungs and bones (20%), or at other sites (5%)\(^4\). Treatment of distant metastases includes LT4 treatment at doses that suppress TSH, local treatment modalities (such as surgery, radiation therapy, radiofrequency ablation) and radioiodine in the 2/3 of patients who demonstrate significant radioiodine uptake in
their metastases. These methods provide a complete remission in only one third of patients with distant metastases. The other patients have radioiodine refractory disease (defined as having at least one lesion without radioiodine uptake or that has progressed within a year following radioiodine treatment or with persistent disease after the administration of a cumulative activity of more than 22GBq (600 mCi) radioiodine). The median survival after the discovery of distant metastases in patients with refractory DTC ranges from 3 to 6 years, but slow tumor growth is common, particularly in young patients with well differentiated tumors.

**Selection of patients for clinical trials.**

Patients with radioiodine refractory metastatic DTC must be accurately characterized concerning all clinical prognostic indicators, including age, performance status, histology, disease extent and location, and progression rate.

Once DTC is found to be refractory to radioiodine, diagnostic procedures should include neck ultrasonography, contrast-enhanced spiral CT scan of the neck, chest and abdomen, and a CT scan or MRI of the brain. Because slowly growing bone metastases are often difficult to visualize on bone scintigraphy, MRI of the spine and pelvis should be considered. A baseline $^{18}$FDG PET scan may complete the work-up to aid disease localization, prognostication as well as response to treatment. It may also point out neoplastic foci with higher FDG uptake that may require in priority local treatment interventions.

Imaging should emphasize identification of all clinically relevant sites of disease, including those tumors large enough to be serially assessed to determine progression and response to therapy, as well as those that might require additional localized intervention, such as surgery, external
radiation therapy, radiofrequency ablation, cryotherapy, cement injection or embolisation. These treatment modalities may permit to postpone the initiation of a systemic treatment. Progression rate is assessed with standardized imaging that is repeated every 6 months, using REsponse Criteria in Solid Tumor (RECIST)\textsuperscript{8,9}. There is no evidence that efficacy of the novel treatment modalities is better at an early stage than later when metastases are larger in size, and in most patients initiation of a systemic treatment can be postponed until disease progression has been documented. Many patients with metastatic DTC can be asymptptomatically stable for long periods of time, and in such patients, the benefits of novel therapies may be largely outweighed by drug toxicities and rigors of clinical trial participation\textsuperscript{2,3}. Patients with measurable lesions and documented progression in a given time interval (between 6 and 15 months) should be considered candidates for systemic treatment. Progression rate that can also be evaluated by the doubling time of serum thyroglobulin (Tg), should always be confirmed by imaging\textsuperscript{8,9}.

**STANDARD SYSTEMIC TREATMENTS**

Cytotoxic chemotherapies provided low response rates in patients with advanced and progressive refractory thyroid cancer and toxicity was high. The more frequently tested agent in thyroid cancer patients is doxorubicin, used either alone or in combination with cisplatin. Tumor response rates range from 0% to 22%, with all responses being partial and only lasting a few months\textsuperscript{10-12}. Newer cytotoxic drugs, such as taxanes, gemcitabine or irinotecan have not been reported in significant series of DTC patients.

**MOLECULAR TARGETED THERAPIES**
Several molecular abnormalities have been defined in DTC and represent potential targets for therapy\textsuperscript{13,14}.

**Molecular targets**

In 80\% of papillary thyroid cancers, activating mutations have been found in genes encoding signalling molecules of the MAPK pathway and are believed to be the initiating event. This includes rearrangements of RET (denoted RET/PTC), and point mutations of RAS and BRAF, with no overlap between these mutations in primary tumors, with an incidence reported in table 1. RET/PTC rearrangements are found more frequently in the classical form, RAS mutations in the follicular variant; and BRAF mutations in the tall cell variant (Table 1). In follicular cancers, RAS mutations and PPAR\textsubscript{γ}-PAX8 rearrangements are the main genetic abnormalities; RET/PTC and BRAF mutations have not been found. In poorly differentiated cancers, NRAS mutation is found in 25\% of cases\textsuperscript{15,16}. The PI3K pathway may also be activated in few papillary and follicular cancers\textsuperscript{17,18}, and acquisition of additional mutations and gene amplifications that activate this pathway may be a common event in poorly differentiated thyroid cancers\textsuperscript{19,20}. Other molecular abnormalities found in these poorly differentiated tumors, which are believed to be secondary events, include TP53 mutations, and overexpression of receptors for epidermal growth factor (EGF), and hepatocyte growth factor (c-Met). These data have been obtained in primary thyroid tumours, and studies in metastatic tissues are still scarce.

Angiogenesis represents another set of potential molecular targets for therapy. Various vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1, KDR)) as well as receptors for the fibroblast growth factor (FGF) and for the Platelet Derived Growth Factor (PDGF) are often overexpressed in the vascular endothelium of thyroid cancer
tissues and they also trigger the MAP kinase signaling pathway\textsuperscript{21,22}. In experimental models, anti-VEGF therapy blocks the growth of differentiated thyroid cancer\textsuperscript{23}.

**Molecular targeted therapies used in thyroid cancer**

Lenvatinib (E7080), motesanib, sorafenib, sunitinib and vandetanib are multi-kinase inhibitors that share the ability of inhibiting Ret and VEGFR, along with other kinases and have been used in DTC with the aim of inhibiting the MAPK pathway and angiogenesis. In contrast, axitinib and pazopanib seem to act only as anti-angiogenic agents. An effort has been made to match molecular pathophysiology to drug mechanism of action, and because BRAF mutation is frequently found in papillary thyroid cancers, sorafenib and PLX4032 have been used in these patients.

**Results of clinical trials**

Available results in DTC patients from phase I and II trials with axitinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitinib, and vandetanib have clearly confirmed the clinical benefits of these compounds. No compound has yet achieved FDA or EMA regulatory approval for therapy of advanced and progressive DTC, but some treatment guidelines recommend the use of available agents for selected patients with progressive metastatic disease based on these phase II results\textsuperscript{1,24}.

**Motesanib.** The first large, international trial of a tyrosine kinase inhibitor for progressive DTC was a phase II study of motesanib (125 mg/d) on 93 patients; 13 (14\%) achieved a confirmed partial response and another 35\% had a stabilization for more than 24 weeks. Median duration of response was 32 weeks, and median PFS was 40 weeks\textsuperscript{25}. 
**Sorafenib.** Sorafenib (400 mg twice daily) treatment in DTC was reported in 4 phase II trials. One trial included 30 patients, of whom 7 had a partial response and another 16 had stable disease\textsuperscript{26}. In another trial in 41 PTC patients, 6 had a partial response and another 23 had stable disease longer than 24 weeks; no partial response was observed among the other 11 patients with FTC or PDTC\textsuperscript{27}. In a third trial involving 32 patients, 8 had a partial response and another 11 had stable disease longer than 24 weeks\textsuperscript{28}. In the fourth trial involving 19 patients, 3 had a partial response\textsuperscript{29}. Efficacy of sorafenib was better in papillary cancer than in poorly differentiated cancer, on lung than on bone metastases, and among PTC patients in those with a BRAF mutation. No effect on 131I uptake was observed in one study\textsuperscript{28}. Sorafenib proved to be active also in children with papillary thyroid cancer\textsuperscript{30}. An ongoing phase III trial is comparing the effect of sorafenib versus placebo on PFS in treatment of naïve patients with radioiodine-refractory, progressive metastatic DTC (NCT00984282).

**Vandetanib.** A randomized phase II trial comparing PFS in refractory DTC treated either with vandetanib (300mg/d) or placebo has been completed in 145 patients\textsuperscript{31}. PFS was significantly improved from 5.8 months in the placebo arm to 11 months in the treatment arm (hazard ratio = 0.63 (95% CI 0.43–0.92)). Unexpectedly, the objective tumor response rate was <5% in the treatment group.

**Sunitinib.** In a phase II trial, sunitinib (37.5 mg daily) in 28 DTC patients with FDG-avid disease on PET scans induced a complete response in 1, a partial response in 7 and stable disease in another 14 patients\textsuperscript{32}. The decrease of FDG uptake at 7 days of sunitinib therapy was greater in patients who had a RECIST response or a stable disease than in those who progressed. In a second phase II trial with 31 evaluable DTC patients with progressive metastases, sunitinib (50
mg/d 4 weeks on-2 weeks off) therapy led to partial responses in 13% and stable disease in 68%.

**Axitinib.** In a phase II study, axitinib (5 mg twice daily) in 45 DTC patients induced a partial response in 14 and a stable disease for more than 16 weeks in another 19 patients. Another phase II trial is still ongoing (NCT00389441).

**Pazopanib.** In a phase II trial, pazopanib (800 mg daily) induced a partial response in 49% of 37 patients. The likelihood of response lasting longer than 1 year was calculated to be 66%, and progression free survival at 1 year was 47%. Interestingly, partial responses were more frequently observed in patients with follicular and Hurthle cell cancers than in those with papillary cancers. Maximum concentration of pazopanib in plasma during cycle one was significantly correlated with radiographic response ($r=-0.40$, $p=0.021$), but 43% of patients required dose reductions owing to adverse events.

**Lenvatinib (E7080).** E7080 showed promising results in thyroid cancer patients in a phase I trial. In a phase II trial, lenvatinib (24 mg) induced a partial response in 45% of 58 patients (in 53% of naïve patients and in 42% of pre-treated patients) and a stable disease in another 46% of patients. Median PFS was 13.3 months. Dose was reduced in 39% of patients and the drug was withdrawn in 29%. Based on these results, a phase III trial comparing the effect of lenvatinib versus placebo on PFS in treatment of patients with progressive refractory DTC will be initiated soon.

**Selective BRAF and MAPK inhibitors.**

RO5185426 (RG7204, PLX 4032) is a selective inhibitor of the V600E mutant BRAF kinase commonly found in PTC. In a phase I trial of RO5185426, among the 3 patients with PTC who were included; 1 experienced a partial response and 2 had disease stabilization. XL 281, which
inhibits both wild type and mutant BRAF kinases, is currently in phase I trial\textsuperscript{39}. Preliminary data described stable disease in 5 PTC patients (including 2 whose tumors contained BRAF mutations). An additional 2 patients with Hurthle cell cancer also were treated with prolonged stable disease, but one patient with anaplastic cancer progressed despite treatment.

Selumetinib (AZD6244), an inhibitor of MEK-1/2, has been studied in a phase II trial involving 39 DTC patients, treated with 100 mg twice daily\textsuperscript{40}. There was 1 partial response, and 21 patients with stable disease, with a median PFS of 32 weeks. An ongoing study focuses on whether selumetinib can re-induce radioiodine sensitivity in previously refractory disease (NCT00970359)\textsuperscript{41}.

**Toxicities of molecularly targeted therapies**

Adverse effects from these targeted therapies are significant, including fatigue, hypertension, anorexia, diarrhea, cytopenias, and skin toxicities. These short or median term side effects may lead to dose reduction in 11-73\% of patients and to withdrawal of drug in 7-25\%. Serum TSH levels should be regularly monitored as they may increase during treatment with any of these kinase inhibitors and this should lead to increase the daily levothyroxine treatment dose\textsuperscript{42}. Given that these treatment modalities may be given for months or even years, further work is needed to minimize toxicities.

The use of BRAF inhibitors (sorafenib, RO5185426) has been associated with the development of cutaneous squamous cell cancers and keratoacanthomas in up to 21\% of treated patients\textsuperscript{38,43}. Paradoxical mitogenic stimulation in cells lacking mutant BRAF has been hypothesized to contribute to development of these neoplasms, and may also underlie development of drug resistance in mutant tumors\textsuperscript{44}. 
Conclusion and perspectives

The majority of patients with DTC can be cured with standard primary treatments; others may survive for decades despite persistent disease, and few patients may require novel therapeutic modalities when the disease burden is large and when progression has been documented. These rare thyroid cancer patients should preferably be included in prospective trials, and even phase I trials that are testing the newest therapies should be considered for patients with progressive thyroid cancer, as these protocols may allow early identification of possibly effective drugs\textsuperscript{45}. Although response criteria in these contemporary trials differ markedly from those evaluating cytotoxic chemotherapy, anti-tumor efficacy of these agents in DTC patients is likely to be much greater than that of earlier chemotherapies. The improvement of PFS that is better related to an improvement of overall survival than response rate, was observed in only one study (a randomized phase II trial, vandetanib versus placebo) and needs to be confirmed by phase III trials. Higher response rates have been reported in recent phase II trials with pazopanib and lenvatinib. Whether any one drug has greater efficacy in distinct histologic subtypes remains to be determined.

Drugs used up to now are all anti-angiogenic and some target a kinase in the MAPK pathway. Future studies should use drugs targeted to already known abnormalities (such as mutated BRAF in PTC) and other pathways such as the PI3K/AKT pathway, and search for other relevant targets that may allow a more personalised treatment to be given. Further trials should also search for other treatment modalities, including combination with cytotoxic chemotherapy or sequential treatment modalities or immunotherapy\textsuperscript{46}. 

Future progress will be made in three directions. Firstly, by improving the knowledge of targets present in each individual tumor and by increasing the number of drugs directed against each of these targets, thyroid cancer patients may benefit from personalized selection of therapies. Secondly, there is an urgent need to test other drugs in thyroid cancer patients and to understand the basis of tumor response. Finally, to increase the accrual of patients, to optimize the experimental design of the protocol, to improve the characterization of tumor tissues, and to improve the tolerance of treatment, the collaborative participation of a multidisciplinary team of endocrinologists, oncologists, nuclear physicians, surgeons, pathologists, laboratory researchers and statisticians should be strongly encouraged through national and international networks.

Conflicts of interest:

MS: Amgen, Astra-Zeneca, Bayer, Exelixis, Eisai, Genzyme, Ipsen Pharma, Roche.

SIS: Amgen, AstraZeneca, Bayer, Exelixis, Eisai, Genzyme, Novo Nordisk, Pfizer, Roche, Veracyte

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
References


5. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* **16**, 1229-42 (2006).


31. Leboulleux, S. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary; follicular; DTC): a randomized, double-blind phase II trial.14th International Thyroid Congress (Paris, 2010).


Table 1. Genetic abnormalities observed in thyroid cancers of follicular origin.

<table>
<thead>
<tr>
<th>Genetic alteration</th>
<th>Function</th>
<th>PTC</th>
<th>FTC</th>
<th>PDTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>RET mutation</td>
<td>tyrosine kinase receptor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RET rearrangement</td>
<td>tyrosine kinase receptor</td>
<td>13-43%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAF mutation</td>
<td>serine threonine kinase</td>
<td>45%</td>
<td></td>
<td>5%</td>
</tr>
<tr>
<td>RAS mutation</td>
<td>small GTPase</td>
<td>0-21%</td>
<td>45%</td>
<td>25%</td>
</tr>
<tr>
<td>PIK3CA amplification/mutation</td>
<td>kinase</td>
<td>3-12%</td>
<td>6-28%</td>
<td>30%</td>
</tr>
<tr>
<td>PAX8/PPARg</td>
<td></td>
<td></td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>P53 mutation</td>
<td></td>
<td></td>
<td></td>
<td>35%</td>
</tr>
</tbody>
</table>

PTC: papillary; FTC: follicular; PDTC: poorly differentiated thyroid cancer
Table 2: Kinase inhibitor activities relevant to thyroid carcinomas

<table>
<thead>
<tr>
<th>Drug</th>
<th>IC 50 (nm)</th>
<th>VEGFR1</th>
<th>VEGFR2</th>
<th>VEGFR3</th>
<th>RET</th>
<th>BRAF</th>
<th>Other targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axitinib</td>
<td></td>
<td>1.2</td>
<td>0.25</td>
<td>0.29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td></td>
<td>2</td>
<td>9</td>
<td>17</td>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motesanib</td>
<td></td>
<td>2</td>
<td>3</td>
<td>6</td>
<td>59</td>
<td></td>
<td>PDGFR, CKIT</td>
</tr>
<tr>
<td>Sorafenib</td>
<td></td>
<td></td>
<td>90</td>
<td>20</td>
<td>49</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Vandetanib</td>
<td></td>
<td>40</td>
<td>110</td>
<td>100</td>
<td></td>
<td></td>
<td>EGFR</td>
</tr>
<tr>
<td>Pazopanib</td>
<td></td>
<td>10</td>
<td>30</td>
<td>47</td>
<td></td>
<td></td>
<td>PDGFR, C-KIT</td>
</tr>
<tr>
<td>Lenvatinib (E7080)</td>
<td></td>
<td>22</td>
<td>4</td>
<td>5</td>
<td>35</td>
<td></td>
<td>PDGFR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FGFR-1 : 25</td>
</tr>
</tbody>
</table>
Table 3: Results obtained in patients with Differentiated Thyroid Carcinoma with kinase inhibitors

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients (n)</th>
<th>PR (%)</th>
<th>SD &gt;6 months (%)</th>
<th>Median PFS (months)</th>
<th>Median OS (months)</th>
<th>Dose reduction for toxicity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vandetanib</td>
<td>Leboulleux (2010)</td>
<td>145</td>
<td>&lt;5</td>
<td>11(vandetanib) vs 5.8 (placebo)</td>
<td>&gt;27</td>
<td>12</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Gupta (2008)</td>
<td>30</td>
<td>23</td>
<td>53</td>
<td>20</td>
<td>NE</td>
</tr>
<tr>
<td></td>
<td>Kloos (2009)</td>
<td>41 PTC</td>
<td>15</td>
<td>56</td>
<td>15</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Hoftijzer (2009)</td>
<td>32</td>
<td>25</td>
<td>34</td>
<td>13.5</td>
<td>NE</td>
</tr>
<tr>
<td>Ahmed (2011)</td>
<td>Ongoing</td>
<td>19</td>
<td>18</td>
<td>82</td>
<td>&gt;24</td>
<td>NE</td>
</tr>
<tr>
<td>Motesanib</td>
<td>Sherman (2008)</td>
<td>93</td>
<td>14</td>
<td>35</td>
<td>9</td>
<td>NE</td>
</tr>
<tr>
<td>Axitinib</td>
<td>Cohen (2008)</td>
<td>45</td>
<td>31</td>
<td>46</td>
<td>18.1</td>
<td>&gt;36</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Cohen (2008)</td>
<td>31</td>
<td>13</td>
<td>68</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carr (2010)</td>
<td>28</td>
<td>29</td>
<td>50</td>
<td>12.8</td>
<td>&gt;24</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Bible (2010)</td>
<td>37 (15 PTC)</td>
<td>49 (33)</td>
<td>11.7</td>
<td>&gt;24</td>
<td>43</td>
</tr>
<tr>
<td>Lenvatinib</td>
<td>Sherman (2011)</td>
<td>58 (43)</td>
<td>45</td>
<td>46</td>
<td>13.3</td>
<td>39</td>
</tr>
</tbody>
</table>

PR: Partial Response; SD: Stable Disease; PFS: Progression Free Survival; OS: Overall Survival